In phase 2 studies, OCA increased insulin sensitivity and reduced markers of liver damage in patients with T2DM and NAFLD [49], and reduced ALT levels, improved NAS scores, prevented and partially reversed fibrogenesis in non-diabetic, pre-cirrhotic NASH patients [50]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.